Orphan drugs for rare diseases

This procedure concerns the designation and marketing of orphan drugs, which are medicines developed for rare diseases. It aims to encourage the development of treatments for conditions affecting a small number of people, ensuring these patients have access to necessary therapies.

This impacts patients with rare diseases, healthcare providers, and the pharmaceutical industry. It seeks to streamline the approval process and provide incentives for companies to invest in research and development for these often-overlooked conditions.